NCT03661216已完成不适用
A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study With Nephure™, an Orally Administered Oxalate Reducing Enzyme
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Within-Subject Urinary Oxalate Excretion
研究概览
简要总结
The purpose of this double-blind study is to determine the effect of reducing oxalates in the diet of healthy volunteers by using Nephure, an oxalate-reducing enzyme, as compared to placebo.
详细描述
This study aims at evaluating the effect from Nephure in reducing dietary oxalate in healthy volunteers on a controlled diet as compared to placebo. Subjects are on a normal diet with controlled oxalate (750mg/day) and calcium (550mg/day) levels for 8 consecutive days. The study is a cross-over design with two four-day treatment periods. The study intends to determine level of reduction in urinary oxalate output as a measure of the effect of Nephure on dietary oxalate when ingested with a meal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Double (participant and investigator) and outcomes assessor
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has granted written informed consent.
- •Subject must be a male or non-pregnant female, at least 18 to 55 years of age at the time of Screening, and non-smoker for at least 3 months at the time of screening and throughout study.
- •Subject has a BMI of 18.5 - 29.9 kg/m2 at the time of Screening.
- •Subject has an estimated glomerular filtration rate (eGFR) of >90 mL/min/1.73 m2 at the time of Screening (GFR is calculated using the NIDDK provided equation at the following web address: www.niddk.nih.gov/health-information/communication-programs/nkdep/laboratory-evaluation/glomerular-filtration-rate-calculators/ckd-epi-adults-conventional-units.)
- •Subject has a urinary oxalate <40.5mg/24 hours at the time of Screening .
- •Subject has a urinary uric acid <750mg/24hour at the time of Screening
- •Subject is in good health as determined by complete physical examination, medical history, vital signs, and laboratory tests.
- •Subject is able to understand the study and be able to comply to the requirements and restrictions, including agreeing to complete the 24-hour urine collections, and has the ability to report their symptoms.
- •Subject is able to comply with all dietary expectations and fluid intake at the discretion of the Principal Investigator (PI).
- •Female subjects must agree to use an acceptable form of birth control from screening through the duration of the study (unless otherwise stated). See section 5.1.1.
排除标准
- •Subject has a history or presence of clinically significant cardiovascular, pulmonary, respiratory, digestive, hepatic, renal, hematological, gastrointestinal (e.g., active bowel disease, known gallstones, GERD, etc.), endocrine, metabolic, immunological, infectious, dermatologic, neurological, psychological, or psychiatric disease or gastrointestinal surgeries (e.g., bowel resection, gastric bypass, cholecystectomy within the 6 months prior to screening, etc.), in the opinion of the Principal Investigator.
- •Subject has received a positive result for urine drug screen at the screening visit or on Day -3, or has a history of positive test result(s) for human immunodeficiency virus (HIV) antibody, Hepatitis B surface antigen or Hepatitis C antibody.
- •Subject has a history of or a current clinically significant medical condition, allergy, food sensitivity (e.g. maltodextrin) or surgical intervention that might significantly compromise the safety of the subject, interfere with study assessments, or impact the validity of the study results, in the opinion of the Principal Investigator.
- •Subject is taking a medication that would indicate significant anxiety, depression, serious or unstable illness, or lack of good general health, that could interfere with the subject's ability to adhere to study instructions, or complete the study, in the opinion of the Principal Investigator and with approval of the Sponsor.
- •Subject is unable or unwilling to discontinue use of dietary supplements (vitamins, minerals, and/or supplements) throughout the duration of the study or has used these products within 7 days prior to screening.
- •Subject has continuously used (not including intermittent or rare PRN use) prescription or over the counter: proton pump inhibitors within 12 weeks of screening; or H2 blockers within 6 weeks of screening; or antacids within 2 weeks of screening.
- •Subject is currently using medication that could affect oxalate handling such as cholestyramine, any carbonic anhydrase inhibitor, any steroid, any diuretic, any immunosuppressant drug, or has received chemotherapy or systemic immunosuppressive drugs within 6 mos. of their screening visit.
- •Subject has had a clinically significant surgical procedure within 3 mos. prior to the Screening visit or planned surgical procedure during the study conduct.
- •Subject has received an investigational product, device, or therapy within 30 days prior to screening.
- •Subject has been on a self-restricted, controlled, or special therapeutic diet, or has had substantial changes in eating or bowel habits, or have had new GI complaints, within 30 days of their screening visit.
- •Subject has been on systemic antibiotic therapy within 6 weeks prior to the screening visit or plans antibiotic therapy during the study conduct.
- •Subject has a history of allergy or hypersensitivity to the study products, its excipients or any comparable products or excipients.
研究组 & 干预措施
Placebo
Placebo Comparator
3g of non-GMO maltodextrin
干预措施: Placebo (Other)
Nephure
Active Comparator
3g of Nephure
干预措施: Nephure Oxalate-reducing Enzyme (Dietary Supplement)
结局指标
主要结局
Within-Subject Urinary Oxalate Excretion
时间窗: 8 days
Milligram of oxalate per 24 hours is determined on dosing days. Within-subject difference in 24 hours urinary oxalate excretion between placebo and Nephure is determined.
Between Groups Urinary Oxalate Excretion
时间窗: 8 days
Milligram of oxalate per 24 hours is determined on dosing days. Mean difference in 24 hours urinary oxalate excretion between placebo and Nephure groups is determined.
次要结局
- Adverse Events(8 days)
- Urinary Oxalate Excretion Compared to Baseline(8 days)
研究者
Donald Burkindine, D.O.
Principal Investigator
QPS-Qualitix
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel SyndromeEnteric HyperoxaluriaNCT05377112Synlogic11
已完成
2 期
A Pilot Study of Oxaloacetate in Subjects With Treated PDParkinson's DiseaseNCT01741701University of Kansas Medical Center33
已完成
不适用
Possible Effects of the Dietary Supplement Magnesium Compared to PlaceboHealth PromotionNCT06332248Dan Hasson1,013
已完成
4 期
Allopurinol in Chronic Heart FailureHyperuricemiaChronic Heart FailureNCT00997542National Heart and Lung Institute16
终止
不适用
Effect of Consuming a Bioactive Compound (EPP) on Joint Health in Healthy AdultsKnee DiscomfortNCT06650670Biosearch S.A.37